Pioneer studies on PC-FCL have highlighted that the absence of BCL-2, CD10, MYC, and IRF4 expression on immunohistochemistry as well as the lack of t (14, 18) at polymerase chain reaction (PCR) or fluorescence in situ hybridization (FISH) should be regarded as helpful tools for the differential diagnosis between indolent PC-FCL and aggressive diseases (systemic FCL with skin involvement; PC-DLBCL, leg type) (2, 9). The gene discussed is BCL2; the disease is diffuse large B-cell lymphoma.